ClinicalTrials.gg
CompletedNCT00452491Updated Oct 5, 2010

MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children

A Phase 3 interventional study of somatropin and somatropin in Fetal Growth Retardation, sponsored by Sanofi. Completed at 1 site in France. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2010-10-05.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
3 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 29 studies in Fetal Growth Retardation with a site in France — 8 open to participants now, 8 under way, 2 of them phase 3. Fetal Growth Retardation · France.

Enrollment
6th of 16
306 · median 207
Started
1993
with 1 other
Phase 3
7 of 29
2 open now
Registered
2nd of 29
by date

Among the 29 studies in Fetal Growth Retardation with a site in France, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 1993, is one of 7 in phase 3, and was the 2nd registered.

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

Browse Fetal Growth Retardation studies →

Open to participants now

8 of the 29 studies in Fetal Growth Retardation with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.

This study: 3 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Fetal Growth Retardation with a site in France, or all of them as a file.
02

Study summary

  1. To test for equivalence in terms of catch-up growth between the 2 therapeutic regimens
  2. To specify the best period of treatment
  3. To assess the efficacy of treatment based on final adult height of these children
03

Conditions studied

  • Fetal Growth Retardation
04

Who can participate

Ages eligible
3 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-pubertal children of either sex presenting with severe early onset intrauterine growth retardation (I.U.G.R.)
  • Height Less Than or Equal to -3 SD

Exclusion criteria

Exclusion Criteria:

  • Age less than 3 years

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    1

    Drug: somatropin

  • Active comparator
    2

    Drug: somatropin

Interventions

  • 0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years

  • 0.2 IU/kg/day 7 days per week given continuously for 3 years

06

What researchers measure

Primary outcomes

  1. Efficacy data : measurement of height

    Time frame: at trimestrial visit

Secondary outcomes

  1. laboratory test assessment and evaluation of bone age

    Time frame: at every other visit

  2. measurement of anti-GH and anti-ECP antibodies

    Time frame: one visit out of four

  3. Tolerance data : undesirable events

    Time frame: throughout the study

07

Study locations

1 site
  • Sanofi-Aventis
    Paris, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 1993, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2007
First posted
Mar 27, 2007
Start
May 1993
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Last update
Oct 5, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00452491
Lead sponsor
Sanofi
First posted
Mar 27, 2007
Start date
May 1993
Primary completion
Apr 2010
Completion
Apr 2010
Last update
Oct 5, 2010

Study contacts

Marie SEBILLE, Dr
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion